  See all
 |
Articles: Myeloproliferative Dz |
Prior Articles
Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells
British Journal of Haematology, 10/16/09
Bortezomib: a new therapeutic option for POEMS syndrome
European Journal of Haematology, 10/13/09 The role of azacitidine in the management of myelodysplastic syndromes (MDS)
Cancer Management and Research, 10/13/09 Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition
Blood, 10/13/09 Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
Cancer Cell, 10/12/09 Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: a single cell study
Haematologica, 10/12/09 Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression
Blood, 10/09/09 Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells
British Journal of Haematology, 10/08/09 Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes
British Journal of Haematology, 10/08/09 Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera
Cancer, 10/08/09 International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
Leukemia, 10/05/09 Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Journal of Clinical Oncology, 10/05/09 Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology, 10/02/09 Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Journal of Clinical Oncology, 10/02/09 Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response
Annals of Hematology, 10/02/09 Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma
Genes, Chromosomes and Cancer, 10/02/09
Exclusive Author Commentary High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors
Cancer Chemotherapy and Pharmacology, 09/30/09 Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndromes associated with chromosome 5q deletion
Haematologica, 09/25/09 Immunomodulation of Multiple Myeloma Bone Disease
Clinical Reviews in Bone and Mineral Metabolism, 09/25/09 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - systematic review and meta-analysis
Haematologica, 09/25/09
|
|
Receive free subspecialty "5-minute updates" via email
|
|
Indexed Journals: Journal of Clinical Oncology, Cancer Research, Annals Oncology
more...
|
187 Available Pages
|
|
